Headlines
- AstraZeneca (NASDAQ:AZN) closed at $78.38, down 0.66%, compared to a minor loss in the S&P 500.
- Over the past month, shares have decreased by 8.14%, trailing behind sector gains.
- Upcoming earnings are anticipated to show significant year-over-year growth in EPS and revenue.
The latest trading session for AstraZeneca (AZN) concluded with shares priced at $78.38, reflecting a decrease of 0.66% from the previous day's close. This decline was slightly less severe than the S&P 500's daily loss of 0.19%, while the Dow rose by 0.09% and the tech-heavy Nasdaq saw a drop of 0.36%.
In the past month, AstraZeneca's shares have experienced an 8.14% decline, which contrasts with the Medical sector's gain of 1.44% and the S&P 500's increase of 2.06%. Market participants are keenly awaiting the company’s upcoming financial results, with projected earnings per share (EPS) estimated at $1.07. This figure represents a 22.99% increase compared to the same quarter last year. Additionally, the latest consensus estimates predict revenue of $13.14 billion, reflecting a 14.37% rise from the prior-year quarter.
For the full year, analysts anticipate earnings of $4.05 per share and revenue of $52.48 billion, indicating year-over-year changes of 11.57% and 14.55%, respectively.
It is crucial to stay informed about recent changes in analyst projections for AstraZeneca, as these revisions often mirror current short-term business trends. Positive adjustments in estimates typically indicate optimism regarding the company's business outlook and profitability.